TICKERNERD
Menu
ZTSZTSHealthcare · Drug Manufacturers - Specialty & Generic

ZTS Stock Forecast: Zoetis, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$74
−2.70% on the day

The 19 Wall Street analysts covering Zoetis, Inc. hold a median 12-month price target of $96 — +29.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$30.5B
Ticker Nerd rank
42 / 100
Median analyst target
$96
Analysts covering
19
Total return, dividends reinvested
1W
+1.6%
1M
+0.3%
YTD
−40.4%
1Y
−50.9%
From 52W high
−52.0%
From 52W low
+3.4%
$71
$154
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zoetis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
98
Quality
96
Issuance
51
Growth
49
Accruals
38
Revisions
29
Size
8
Momentum
7

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26ZTSHigh $160Median $96Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says19 analysts
10 Buy9 Hold0 Sell
Low $80Median $96High $160

The green dot is the last close — the median target sits +29.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 10 moved it down.

DateFirmActionRatingTarget
11 Aug 2026BNP ParibasMaintainsOutperform$146 → $110
11 Aug 2026CitigroupMaintainsBuy$112 → $96
10 Aug 2026Piper SandlerMaintainsNeutral$90 → $80
7 Aug 2026JP MorganMaintainsOverweight$130 → $115
7 Aug 2026UBSMaintainsNeutral$85 → $80
6 Aug 2026William BlairDowngradeMarket Perform—
27 July 2026UBSMaintainsNeutral—
27 July 2026UBSMaintainsNeutral$99 → $85
22 July 2026Morgan StanleyMaintainsOverweight$115 → $99
22 July 2026Morgan StanleyMaintainsOverweight—
6 July 2026HSBCMaintainsBuy—
6 July 2026HSBCMaintainsBuy$140 → $95
1 July 2026BarclaysMaintainsEqual-Weight—
1 July 2026BarclaysMaintainsEqual-Weight$136 → $85
30 June 2026TD CowenMaintainsBuy—
30 June 2026TD CowenMaintainsBuy$150 → $104
26 June 2026StifelMaintainsHold—
27 May 2026Argus ResearchDowngradeHold—
22 May 2026StifelMaintainsHold—
18 May 2026CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ZTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−7.1%
Analysts raising
0
Analysts cutting
6
Fundamentals

Zoetis, Inc. (ZTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.0×

Cheaper than 55% of US stocks

Price / sales
3.2×

Cheaper than 40% of US stocks

Price / book
9.8×

Cheaper than 11% of US stocks

EV / EBITDA
9.4×

Cheaper than 41% of US stocks

Growth & margins
Revenue growth (YoY)
−0.2%

Higher than 28% of US stocks

Earnings growth (YoY)
−4.8%

Higher than 30% of US stocks

Gross margin
72.7%

Higher than 85% of US stocks

Operating margin
40.7%

Higher than 92% of US stocks

Net margin
27.7%

Higher than 87% of US stocks

Returns & dividend
Return on equity
64.9%

Higher than 94% of US stocks

Return on assets
15.4%

Higher than 97% of US stocks

Dividend yield
2.9%

Higher than 64% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ZTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ZTSZoetis, Inc.$30.5B
42
UTHRUnited Therapeutics Corp.$21.2B
82
VTRSViatris, Inc.$18.7B
100
NBIXNeurocrine Biosciences, Inc.$15.2B
89
ELANElanco Animal Health, Inc.$11.8B
98
ALKSAlkermes Plc$8.1B
60
HIMSHims & Hers Health, Inc.$6.6B
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zoetis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZTS news & analysis

Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap

Seeking Alpha · 16 Aug 2026negative

Zoetis reported mixed Q2 results and cut its forward guidance, which reduced the stock's margin of safety. Other business segments performed well, partially offsetting weakness in U.S. pet-related sales, and the article notes the risk/reward profile still favors bulls.

Why it matters — ZTS watchers would care because the guidance cut and mixed quarterly results signal cooling momentum in key pet-related sales even as other segments provide some offset.

Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense

Seeking Alpha · 14 Aug 2026neutral

Following a multiyear drawdown, Zoetis now trades at roughly 12x forward earnings with nearly a 3% dividend yield and gross margins above 70%. The company faces competition, weaker U.S. companion animal sales, and reduced guidance, but maintains core profitability, market dominance, share repurchases, and a healthy balance sheet despite about $9 billion in long-term debt.

Why it matters — The item gives ZTS watchers a snapshot of the company's valuation, profitability, capital returns, and the competitive and demand pressures affecting it.

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Business Wire · 13 Aug 2026positive

Zoetis announced that the FDA granted Emergency Use Authorization for its product Simparica Trio to treat New World screwworm infestations in dogs and puppies. The larvae of this parasite feed on living tissue of animals, including pets and livestock.

Why it matters — This EUA expands the approved use of Simparica Trio, potentially making Zoetis the key provider of a treatment for a serious parasitic threat affecting companion animals and livestock.

Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs

Reuters · 13 Aug 2026positive

The U.S. FDA issued an emergency use authorization for Zoetis' flea and tick drug to treat New World screwworm infestations in dogs and puppies. The authorization was granted on Thursday, according to Reuters.

Why it matters — The FDA emergency use authorization expands the approved applications for a Zoetis animal-health product, potentially broadening its market use.

Diamond Hill Mid Cap Fund Q2 2026 Contributors And Detractors

Seeking Alpha · 11 Aug 2026negative

Diamond Hill Mid Cap Fund reported strong second-quarter equity market returns driven by robust corporate earnings and a resilient domestic economy. Zoetis was listed among the fund's key detractors for the quarter, alongside Huntington Ingalls and Wix.com.

Why it matters — The fund's identification of Zoetis as a key detractor indicates the stock underperformed within this mid-cap portfolio during the second quarter.

FAQ

Frequently asked questions about ZTS stock

What is the ZTS stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Zoetis, Inc. have a median 12-month price target of $96, with estimates ranging from $80 to $160. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZTS stock a buy right now?

Of the 19 analysts covering Zoetis, Inc., 10 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zoetis, Inc. 42 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZTS?

As at 15 Aug 2026, Zoetis, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will ZTS stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +29.4% from the last close, and Ticker Nerd's factor model ranks Zoetis, Inc. 42 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZTS stock forecast for 2030?

No analyst covering Zoetis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $160 over the next 12 months.

How has ZTS stock performed over the past year?

Zoetis, Inc. returned -50.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zoetis, Inc. do?

Zoetis Inc. is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health solutions.

What is the latest news on ZTS?

The most recent item we track (Seeking Alpha, 16 Aug 2026): "Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap". Zoetis reported mixed Q2 results and cut its forward guidance, which reduced the stock's margin of safety. Other business segments performed well, partially offsetting weakness in U.S. pet-related sales, and the article notes the risk/reward profile still favors bulls.

Company

About Zoetis, Inc.

Zoetis Inc. is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health solutions. Its products serve both companion animals, such as dogs, cats, and horses, and livestock, including cattle, swine, poultry, fish, and sheep. Zoetis offers a broad portfolio spanning parasiticides, vaccines, dermatology treatments, anti-infectives, pain and sedation therapies, and nutritional and other non-pharmaceutical products, supported by point-of-care diagnostic tools, laboratory services, and monitoring technologies. The company markets its solutions primarily to veterinarians, livestock producers, and pet owners, playing a key role in supporting animal health, food production efficiency, and pet care standards worldwide. Zoetis Inc. operates across the United States and international markets and is headquartered in Parsippany, New Jersey.

CEO Ms. Kristin C. Peck · 14,500 employees · United States · https://www.zoetis.com